Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, and MRI in cancer diagnosis.
Automated population of structured magnetic resonance imaging staging reports for rectal cancer from free-text radiology reports using deep learning–based natural language processing
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.
Author Correction: Hepatocellular carcinoma
Author Correction: Hepatocellular carcinoma.
Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel
Prognostic Role of the Progression of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy.
REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria.
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.
Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies.
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Imaging Diagnosis of Hepatocellular Carcinoma: A State-of-the-Art Review.
Delta-radiomics in cancer immunotherapy response prediction: A systematic review.
Looking for appropriateness in follow-up CT of oncologic patients: Results from a cross-sectional study.
Diagnostic Role of Native T1 Mapping Compared to Conventional Magnetic Resonance Techniques in Cardiac Disease in a Real-Life Cohort.
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study
Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies.
Cardiac Magnetic Resonance in Fabry Disease: Morphological, Functional, and Tissue Features.
A New SteatoScore in the Evaluation of Non-Alcoholic Liver Disease in Oncologic Patients.
Hepatocellular carcinoma.
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).